Navigation Links
Ray TFC/ Unite System

ProductsRay TFC/ Unite System
Company Stryker Corporation
Item Ray TFC/ Unite System
Features 
  • Same Superior Biomechanics as Ray TFC: Load sharing, 70% Fenestrations, Thread design
  • Strategic Lateral Arches: Medial/Lateral saving of 3mm per implant: addresses narrow disc space
  • Optimal Delivery System: Dual tang design places TFC and UNITE closely together
    • Description The Ray TFC Unite Device is the anterior alternative to the Ray TFC posterior system. The Ray TFC Unite device features the same 70% fenestrations as Ray TFC. The maximum bone-to-bone contact offered by fenestrations is paramount in the formation of new bone. As with Ray TFC the Ray TFC Unite system promotes load sharing between the device and the spine.* In an anterior procedure where the Unite system is used, one Ray TFC Device is interdigitated with one Ray TFC Unite Device. This interdigitation is made possible by the unique design of the Ray TFC Unite device. Lateral arches medially and laterally have been incorporated into the design of the Ray TFC Unite device. These arches allow a Ray TFC device to be very closely aligned (interdigitated) with a Unite device. The two-cage construct is introduced to the interbody space with the use of a dual tang retractor. As with the Ray TFC Device, the Ray TFC UniteDevice has established a proven record of clinical success buttressed by a series of white papers and patient follow-up studies.*
    Info Stryker Corporation
    Customer Service: (269) 385-2600
    Web site: http://www.stryker.com/

    Related medicine products :

    1. Glycohemoglobin Unitest Set
    2. Salter AIRE Plus® Portable Treatment Compressor (230V) United Kingdom Model
    3. Silicone Oil Cannula System - 20 Gauge
    4. Silicone Oil Cannula System - 19 Gauge
    5. SuperVu Galilean System
    6. KOWA nonmyd 7 / VK-2 Digital Imaging System
    7. KOWA nonmyd a-D / VK-2 Digital Imaging System
    8. Refraction System RT-2100
    9. Odyssey Phacoemulsification System
    10. SIStem Phacoemulsification System
    11. Precisionist Phacoemulsification System
    Measure SpO2 and tcpCO2 with a single sensor.
    The TCM400 is the first and only portable instrument to provide up to six simultaneous measurements of transcutaneous oxygen tension (tcpO2)
    Two separate sensors provide continuous measurement of tcpO2/tcpCO2 and SpO2.
    ...versity is the only online source of nationally ac...sts, critical care nurses and other healthcare pro...re available online 24/7, so you can take them at ... and a certificate is issued upon course completio...
    Medicine Products:
    (Date:12/2/2008)...swire/ -- Today, the University HealthSystem,Cons... has been appointed Vice,President, Quality and P...ing,a year and a half as director of quality and ...al in Chicago, Ill. Previously, she was the senio...area. , "Julie,s experience at Northwestern...
    (Date:12/2/2008)...ec. 1 diaDexus, Inc. today,announ...mated format of the,PLAC Test for Lp-PLA2. This a...unning on a wide range of clinical chemistry analy...g Administration (FDA) in December 2007. diaDexus ...d PLAC Test to Europe. , The PLAC Test is t...
    (Date:12/2/2008)...onash University, The Brigham and Women,s Hospital...ceuticals has found a new drug with the potential ... shift work. , Dr Shantha Rajaratnam from Monas...d Psychological Medicine said tasimelteon, a drug ...uld be a highly effective treatment for circadian ...
    (Date:12/2/2008)...for an Injunction in Federal Court to Reclaim Over...ewswire-USNewswire/ -- Registered nurses for River...al Medical Center, filed a Fair Labor Standards Ac...day to stop the county from violating federal law ...ho are seeking to represent all 867 registered nur...
    Breaking Medicine News(10 mins):Health News:Julie Cerese Returns to University HealthSystem Consortium as Vice President of Quality and Patient Safety 2Health News:diaDexus Receives CE Mark Certification for the PLAC(R) Test 2Health News:New medication brings hope of jet lag cure 2Health News:Riverside County Registered Nurses File a Lawsuit to Stop County's Violation of Federal Law 2
    ... beats per minute (BPM). If the rhythm of the hear...rave danger. This was the case for Jeffrey Nauser....er repeat trips to the Emergency Room where his li...frey’s story began four years ago while on a job i...
    ...ouch to recover before returning to sports, but an...east not yet. // One Ohio State University Medical...hanical support devices for the heart will be put ...heart to rest and recover itself. Right now, such ...
    ...nd patients about commonly used thyroid medication...of the drugs, a senior endocrinologist has warned.... University and The Alfred and Epworth Hospitals i...ion (PI) for thyroid medications published in phar...
    ...search project, titled 'Sun Safe in the Middle Sch...January issue of "Pediatrics”, was undertaken to s...the risks of skin cancer. //The importance of usin...he risk of skin cancer was the keynote of the proj...
    Other Medicine News:Health News:Rewiring the Heart 2Health News:Pumps Someday May Allow Patients to Recover Their Own Hearts 2Health News:Pumps Someday May Allow Patients to Recover Their Own Hearts 3Health News:Medicine Information Out of Date 2
    (Date:12/2/2008)...CHICAGO, Dec. 3 Breast-... detection of cancers not found on mammograms or b...oday at the annual meeting of,the Radiological So...identify the most difficult to detect breast cance...achel F. Brem, M.D., professor of,radiology and d...
    (Date:12/2/2008)...SKOKIE, Ill., Dec. 2 Horizon Thera... company, today announced that two pivotal,Phase ...ct candidate, HZT-501,met all primary endpoints....tion product containing ibuprofen and famotidine, ...n in the incidence of non-steroidal,anti-inflamma...
    (Date:12/1/2008)...ROCKVILLE, Md., Dec. 1 V...s publication in The Lancet , one of the world,s ...ls of its novel circadian regulator, experimental ...y Rajaratnam et al(1) is entitled "Melatonin agoni...ter sleep-time shift: two randomised controlled mu...
    (Date:12/1/2008)...Baby Girl with Hypophosphatasia Treated With ENB-0... in Winnipeg , , MONTREAL, Dec. 1 /PRNewswi... company focused on developing novel therapeutics ...he first infant patient in its clinical program fo...ing Enzyme Replacement Therapy (ERT) with ENB-0040...
    Breaking Medicine Technology:New Breast Imaging Technology Targets Hard-to-Detect Cancers 2New Breast Imaging Technology Targets Hard-to-Detect Cancers 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Acupuncture reduces pain and dysfunction in head and neck cancer patients after neck dissection 20751 1Acupuncture reduces pain and dysfunction in head and neck cancer patients after neck dissection 20751 2VELCADE 28R 29 28Bortezomib 29 for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Mult 2254 1VELCADE 28R 29 28Bortezomib 29 for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Mult 2254 2VELCADE 28R 29 28Bortezomib 29 for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Mult 2254 3VELCADE 28R 29 28Bortezomib 29 for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Mult 2254 4VELCADE 28R 29 28Bortezomib 29 for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Mult 2254 5VELCADE 28R 29 28Bortezomib 29 for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Mult 2254 6Patients with Pancreatic Cancer Can Benefit From Avastin 28R 29 Plus Tarceva 28R 29 2251 1Patients with Pancreatic Cancer Can Benefit From Avastin 28R 29 Plus Tarceva 28R 29 2251 2Patients with Pancreatic Cancer Can Benefit From Avastin 28R 29 Plus Tarceva 28R 29 2251 3Chemo May Limit Fertility in Breast Cancer Survivors 20748 1Chemo May Limit Fertility in Breast Cancer Survivors 20748 2
    ...ontinue Phase II Profiling,in Diabetic Patients ,...ne 2007-Speedel,(SWX: SPPN) today announced that i... development of its family of renin inhibitors wit...f-concept clinical,trial with SPP635 for the treat...lts, the company is to continue developing SPP635 ...
    ...(BUSINESS WIRE)--Jun 28, 2007,- Progenics Pharmace...cals, a division of Wyeth (NYSE: WYE), today annou...l extension study of,subcutaneous methylnaltrexone...(OIC) in patients with advanced illness. The resul...nal Association of,Supportive Care in Cancer (MASC...
    Other Medicine Technology:Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 2Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 3Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 4Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 5Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 6Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 7Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 8Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 2Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 3Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 4Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 5Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 6